Genomic landscape and chronological reconstruction of driver events in multiple myeloma
Francesco Maura, Niccoló Bolli, Nicos Angelopoulos, Kevin J Dawson, Daniel Leongamornlert, Inigo Martincorena, Thomas J Mitchell, Anthony Fullam, Santiago Gonzalez, Raphael Szalat, Federico Abascal, Bernardo Rodriguez-Martin, Mehmet Kemal Samur, Dominik Glodzik, Marco Roncador, Mariateresa Fulciniti, Yu Tzu Tai, Stephane Minvielle, Florence Magrangeas, Philippe Moreau, Paolo Corradini, Kenneth C Anderson, Jose M C Tubio, David C Wedge, Moritz Gerstung, Hervé Avet-Loiseau, Nikhil Munshi, Peter J Campbell, Francesco Maura, Niccoló Bolli, Nicos Angelopoulos, Kevin J Dawson, Daniel Leongamornlert, Inigo Martincorena, Thomas J Mitchell, Anthony Fullam, Santiago Gonzalez, Raphael Szalat, Federico Abascal, Bernardo Rodriguez-Martin, Mehmet Kemal Samur, Dominik Glodzik, Marco Roncador, Mariateresa Fulciniti, Yu Tzu Tai, Stephane Minvielle, Florence Magrangeas, Philippe Moreau, Paolo Corradini, Kenneth C Anderson, Jose M C Tubio, David C Wedge, Moritz Gerstung, Hervé Avet-Loiseau, Nikhil Munshi, Peter J Campbell
Abstract
The multiple myeloma (MM) genome is heterogeneous and evolves through preclinical and post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using sequences from 67 MM genomes serially collected from 30 patients together with public exome datasets. Bayesian clustering defines at least 7 genomic subgroups with distinct sets of co-operating events. Focusing on whole genome sequencing data, complex structural events emerge as major drivers, including chromothripsis and a novel replication-based mechanism of templated insertions, which typically occur early. Hyperdiploidy also occurs early, with individual trisomies often acquired in different chronological windows during evolution, and with a preferred order of acquisition. Conversely, positively selected point mutations, whole genome duplication and chromoplexy events occur in later disease phases. Thus, initiating driver events, drawn from a limited repertoire of structural and numerical chromosomal changes, shape preferred trajectories of evolution that are biologically relevant but heterogeneous across patients.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015;125:1870–1876. doi: 10.1182/blood-2014-10-567370.
- Manier S, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 2017;14:100–113. doi: 10.1038/nrclinonc.2016.122.
- Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat. Rev. Cancer. 2012;12:335–348. doi: 10.1038/nrc3257.
- Walker BA, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 2015;6:6997. doi: 10.1038/ncomms7997.
- Bolli N, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 2014;5:2997. doi: 10.1038/ncomms3997.
- Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467–472. doi: 10.1038/nature09837.
- Lohr JG, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91–101. doi: 10.1016/j.ccr.2013.12.015.
- Walker BA, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 2015;33:3911–3920. doi: 10.1200/JCO.2014.59.1503.
- Bolli N, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32:2604–2616. doi: 10.1038/s41375-018-0037-9.
- Keats JJ, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067–1076. doi: 10.1182/blood-2012-01-405985.
- Magrangeas F, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013;27:473–481. doi: 10.1038/leu.2012.226.
- Walker BA, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28:384–390. doi: 10.1038/leu.2013.199.
- Walker BA, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587–597. doi: 10.1182/blood-2018-10-875138.
- Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, Alexandrov L B, Fullam A, Martincorena I, Dawson K J, Angelopoulos N, Samur M K, Szalat R, Zamora J, Tarpey P, Davies H, Corradini P, Anderson K C, Minvielle S, Neri A, Avet-Loiseau H, Keats J, Campbell P J, Munshi N C, Bolli N. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2017;32(4):1043–1047. doi: 10.1038/leu.2017.345.
- Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349:1483–1489. doi: 10.1126/science.aab4082.
- Martincorena I, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348:880–886. doi: 10.1126/science.aaa6806.
- Martincorena I, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171:1029–1041. doi: 10.1016/j.cell.2017.09.042.
- Krysiak K, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129:473–483. doi: 10.1182/blood-2016-07-729954.
- Seiler M, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018;23:282–296. doi: 10.1016/j.celrep.2018.01.088.
- Puente XS, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526:519–524. doi: 10.1038/nature14666.
- Reddy A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481–494. doi: 10.1016/j.cell.2017.09.027.
- Hoang Phuc H., Dobbins Sara E., Cornish Alex J., Chubb Daniel, Law Philip J., Kaiser Martin, Houlston Richard S. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia. 2018;32(11):2459–2470. doi: 10.1038/s41375-018-0103-3.
- Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 2016;374:2209–2221. doi: 10.1056/NEJMoa1516192.
- Grinfeld J, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N. Engl. J. Med. 2018;379:1416–1430. doi: 10.1056/NEJMoa1716614.
- Li, Y. et al. Patterns of structural variation in human cancer. Preprint at: 10.1101/181339v1 (2017).
- Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell. 2013;152:1226–1236. doi: 10.1016/j.cell.2013.02.023.
- Li Y, et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature. 2014;508:98–102. doi: 10.1038/nature13115.
- Maciejowski J, Li Y, Bosco N, Campbell PJ, de Lange T. Chromothripsis and kataegis induced by telomere crisis. Cell. 2015;163:1641–1654. doi: 10.1016/j.cell.2015.11.054.
- Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood. 2011;118:675–678. doi: 10.1182/blood-2011-03-344069.
- Affer M, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28:1725–1735. doi: 10.1038/leu.2014.70.
- Fabris S, et al. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosom Cancer. 2005;42:117–127. doi: 10.1002/gcc.20123.
- Chavan SS, et al. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 2017;7:e535. doi: 10.1038/bcj.2017.12.
- Bolli, F. et al. Genomic patterns of progression in smoldering multiple myeloma. Nat. Commun.9, 3363 (2018).
- Rasche L, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat. Commun. 2017;8:268. doi: 10.1038/s41467-017-00296-y.
- Gerstung, G. et al. The evolutionary history of 2,658 cancers. Preprint at: 10.1101/161562v2 (2018).
- Walker Brian A., Mavrommatis Konstantinos, Wardell Christopher P., Ashby T. Cody, Bauer Michael, Davies Faith, Rosenthal Adam, Wang Hongwei, Qu Pingping, Hoering Antje, Samur Mehmet, Towfic Fadi, Ortiz Maria, Flynt Erin, Yu Zhinuan, Yang Zhihong, Rozelle Dan, Obenauer John, Trotter Matthew, Auclair Daniel, Keats Jonathan, Bolli Niccolo, Fulciniti Mariateresa, Szalat Raphael, Moreau Phillipe, Durie Brian, Stewart A. Keith, Goldschmidt Hartmut, Raab Marc S., Einsele Hermann, Sonneveld Pieter, San Miguel Jesus, Lonial Sagar, Jackson Graham H., Anderson Kenneth C., Avet-Loiseau Herve, Munshi Nikhil, Thakurta Anjan, Morgan Gareth. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2018;33(1):159–170. doi: 10.1038/s41375-018-0196-8.
- Keane N, et al. MYC translocations identified by sequencing panel in smoldering multiple myeloma strongly predict for rapid progression to multiple myeloma. Blood. 2017;130:393. doi: 10.1182/blood-2017-06-789156.
- Nik-Zainal S, et al. The life history of 21 breast cancers. Cell. 2012;149:994–1007. doi: 10.1016/j.cell.2012.04.023.
- Alexandrov LB, et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 2015;47:1402–1407. doi: 10.1038/ng.3441.
- Mitchell TJ, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173:611–623. doi: 10.1016/j.cell.2018.02.020.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–1760. doi: 10.1093/bioinformatics/btp324.
- Jones D, et al. cgpCaVEManWrapper: simple execution of CaVEMan in order to detect somatic single nucleotide variants in NGS data. Curr. Protoc. Bioinform. 2016;56:15 10 11–15 10 18. doi: 10.1002/cpbi.20.
- Nik-Zainal S, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47–54. doi: 10.1038/nature17676.
- Raine KM, et al. cgpPindel: identifying somatically acquired insertion and deletion events from paired end sequencing. Curr. Protoc. Bioinforma. 2015;52:15 17 11–12.
- Coletta A, et al. InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor. Genome Biol. 2012;13:R104. doi: 10.1186/gb-2012-13-11-r104.
- Raine KM, et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr. Protoc. Bioinforma. 2016;56:15 19 11–15 19 17. doi: 10.1002/cpbi.17.
- Nik-Zainal S, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979–993. doi: 10.1016/j.cell.2012.04.024.
- Bartlett, M. & Cussens, J. Integer linear programming for the Bayesian network structure learning problem. Artificial Intelligence. 244, 258–271 (2015).
- Gamrath, G. et al. The SCIP Optimization suite 3.2. (ZIB, Takustr.7, 14195 Berlin, 2016).
- Wielemaker J, Schrijvers T, Triska M, Lager T. SWI-Prolog. Theory Pract. Log. Program. 2012;12:67–96. doi: 10.1017/S1471068411000494.
- Clarkson DB, Fan Y, Joe H. A remark on algorithm 643: FEXACT: an algorithm for performing Fisher’s exact test in r × c contingency tables. ACM Trans. Math. Softw. 1993;19:484–488. doi: 10.1145/168173.168412.
- Paulsson K, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat. Genet. 2015;47:672–676. doi: 10.1038/ng.3301.
- Yates LR, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 2015;21:751–759. doi: 10.1038/nm.3886.
Source: PubMed